Definition of “suboptimal” response. These criteria are based on imatinib monotherapy, 400 mg daily for 6 to 12 months.
| Abbreviations: RQ-PCR, real-time quantitative polymerase chain reaction | |
| Broadly applicable: | |
| 1. | Failure to achieve a complete hematological response after 3 months |
| 2. | Failure to achieve any significant cytogenetic response after 6 months |
| 3. | Failure to achieve a major cytogenetic response after 1 year |
| Applicable with access to reliable specialized facilities: | |
| 4. | Failure to achieve a 3-log reduction in BCR-ABL/ABL ratios compared to pre-treatment levels |
| 5. | Detection of ABL kinase domain mutations, particularly those in the P loop. Mutation analysis triggered by 2-fold rise in BCR-ABL/ABL ratio by RQ-PCR |
| Abbreviations: RQ-PCR, real-time quantitative polymerase chain reaction | |
| Broadly applicable: | |
| 1. | Failure to achieve a complete hematological response after 3 months |
| 2. | Failure to achieve any significant cytogenetic response after 6 months |
| 3. | Failure to achieve a major cytogenetic response after 1 year |
| Applicable with access to reliable specialized facilities: | |
| 4. | Failure to achieve a 3-log reduction in BCR-ABL/ABL ratios compared to pre-treatment levels |
| 5. | Detection of ABL kinase domain mutations, particularly those in the P loop. Mutation analysis triggered by 2-fold rise in BCR-ABL/ABL ratio by RQ-PCR |